MS-325 EPIX.
EPIX is developing MS-325 (AngioMARK), an intravascular magnetic resonance contrast agent for use in the imaging of blood vessels and blood flow in patients with cardiovascular disease, including peripheral vascular disease (PVD). In June 1999, EPIX and Mallinckrodt began phase III trials of MS-325 for the detection of aortoiliac occlusive disease in patients with PVD or abdominal aortic aneurysm [328640]. NDAs for the peripheral and cardiac applications were expected in 1999 and 2000, respectively [275240], [325717]. MS-325 has also shown promise in demonstrating the presence of microscopic muscular dystrophy, as well as monitoring the effects of gene therapy in a mouse model of the disease [360974]. MS-325 is a stable complex of gadolinium and an organic chelating agent. It resembles approved agents in terms of stability, safety and elimination profile, but possesses novel chemical groups which allow it to bind reversibly to albumin. This retains the agent in the blood and, via a patented biophysical phenomenon, enhances the magnetic properties of the gadolinium ion approximately ten-fold.